SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ASTM-AASTROM BIOSCIENCES: STEM CELL RESEARCH
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: TH who wrote (577)2/23/1999 12:32:00 AM
From: TheAlaskan  Read Replies (2) of 1084
 
ASTM-PR soon-two sources

I spoke with Fran Devellis, hired IR and Todd Simpson today.

1. ASTM is on track. They both state that many companies do not make immediate sale just because the get CE approval.(Can anyone in biotechs confirm this?) However, ASTM has to conduct internal testing and certification on devices before shipping. ASTM is working out some internal paperwork ensuring equipment meets internal specs. Nothing is stopping the company from external or regulatory sources. They can sell today.

2. Asked if there was a distribution problem or a production problem: none whatsoever. They have good Mfrs. for devices. On the question of Public relations...they understand that cord blood/transplants is hot topic in media and that they could readily issue information to draw attention to themselves. It appears that they would prefer to be found rather than draw attention to themselves ( I can only suspect that they want a steady share price increase as opposed to a volatile increase with a related decline after the initial attention wears off).

3. PR will come "very soon" on their European Launch and first sale.
They are talking to customers in Europe now.

4. I asked Fran on Duke University study NEJM article. All American clinical tests are related to cancer treatment, not other applications. Europe will have non-cancer applications first and then they will move this information and applications to US. Their eventual goal is to have ASTM treatments and devices on an array of stem cell replication/ treatment/ applications.

Bottomline is news is coming. How big and how much????

The Alaskan

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News